Logo image of NTRA

NATERA INC (NTRA) Stock Fundamental Analysis

NASDAQ:NTRA - Nasdaq - US6323071042 - Common Stock - Currency: USD

162.31  -5.88 (-3.5%)

After market: 157.896 -4.41 (-2.72%)

Fundamental Rating

4

Overall NTRA gets a fundamental rating of 4 out of 10. We evaluated NTRA against 572 industry peers in the Biotechnology industry. NTRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year NTRA has reported negative net income.
NTRA had a positive operating cash flow in the past year.
NTRA had negative earnings in each of the past 5 years.
In the past 5 years NTRA always reported negative operating cash flow.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

NTRA's Return On Assets of -13.49% is amongst the best of the industry. NTRA outperforms 85.44% of its industry peers.
The Return On Equity of NTRA (-24.44%) is better than 82.24% of its industry peers.
Industry RankSector Rank
ROA -13.49%
ROE -24.44%
ROIC N/A
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 57.66%, NTRA is in the better half of the industry, outperforming 78.51% of the companies in the same industry.
NTRA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

More info and screens

5

2. Health

2.1 Basic Checks

NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NTRA has more shares outstanding
The debt/assets ratio for NTRA has been reduced compared to a year ago.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

2.2 Solvency

An Altman-Z score of 17.72 indicates that NTRA is not in any danger for bankruptcy at the moment.
The Altman-Z score of NTRA (17.72) is better than 92.18% of its industry peers.
A Debt/Equity ratio of 0.42 indicates that NTRA is not too dependend on debt financing.
The Debt to Equity ratio of NTRA (0.42) is worse than 73.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z 17.72
ROIC/WACCN/A
WACC9.39%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M

2.3 Liquidity

NTRA has a Current Ratio of 4.39. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
NTRA's Current ratio of 4.39 is in line compared to the rest of the industry. NTRA outperforms 49.38% of its industry peers.
NTRA has a Quick Ratio of 4.23. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
NTRA's Quick ratio of 4.23 is in line compared to the rest of the industry. NTRA outperforms 49.91% of its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.23
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

NTRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.06%, which is quite impressive.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 54.93%.
NTRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.25% yearly.
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.63%
Revenue 1Y (TTM)54.93%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Sales Q2Q%63.9%

3.2 Future

Based on estimates for the next years, NTRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.34% on average per year.
The Revenue is expected to grow by 19.13% on average over the next years. This is quite good.
EPS Next Y59.52%
EPS Next 2Y29.44%
EPS Next 3Y26.09%
EPS Next 5Y17.34%
Revenue Next Year56.77%
Revenue Next 2Y31.18%
Revenue Next 3Y26.55%
Revenue Next 5Y19.13%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

A more expensive valuation may be justified as NTRA's earnings are expected to grow with 26.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.44%
EPS Next 3Y26.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NATERA INC

NASDAQ:NTRA (2/21/2025, 8:00:01 PM)

After market: 157.896 -4.41 (-2.72%)

162.31

-5.88 (-3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners92.42%
Inst Owner Change3.37%
Ins Owners3.53%
Ins Owner Change2.86%
Market Cap21.43B
Analysts85.19
Price Target192.97 (18.89%)
Short Float %3.53%
Short Ratio3.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.48%
Min EPS beat(2)55.66%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)37.22%
Min EPS beat(4)13.75%
Max EPS beat(4)57.31%
EPS beat(8)7
Avg EPS beat(8)20.69%
EPS beat(12)10
Avg EPS beat(12)14.61%
EPS beat(16)11
Avg EPS beat(16)7.34%
Revenue beat(2)2
Avg Revenue beat(2)18.71%
Min Revenue beat(2)18.14%
Max Revenue beat(2)19.28%
Revenue beat(4)4
Avg Revenue beat(4)14.55%
Min Revenue beat(4)6.8%
Max Revenue beat(4)19.28%
Revenue beat(8)7
Avg Revenue beat(8)8.56%
Revenue beat(12)10
Avg Revenue beat(12)6.32%
Revenue beat(16)14
Avg Revenue beat(16)7.47%
PT rev (1m)4.14%
PT rev (3m)40.18%
EPS NQ rev (1m)20.17%
EPS NQ rev (3m)33.07%
EPS NY rev (1m)6.73%
EPS NY rev (3m)23.84%
Revenue NQ rev (1m)4.54%
Revenue NQ rev (3m)15.07%
Revenue NY rev (1m)1.14%
Revenue NY rev (3m)9.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.99
P/FCF N/A
P/OCF 869.23
P/B 24.39
P/tB 24.39
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)0.19
OCFY0.12%
SpS11.6
BVpS6.65
TBVpS6.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.49%
ROE -24.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.66%
FCFM N/A
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%
F-Score7
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 227.12%
Cap/Sales 4.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.23
Altman-Z 17.72
F-Score7
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)296.37%
Cap/Depr(5y)236.21%
Cap/Sales(3y)5.79%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.63%
EPS Next Y59.52%
EPS Next 2Y29.44%
EPS Next 3Y26.09%
EPS Next 5Y17.34%
Revenue 1Y (TTM)54.93%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Sales Q2Q%63.9%
Revenue Next Year56.77%
Revenue Next 2Y31.18%
Revenue Next 3Y26.55%
Revenue Next 5Y19.13%
EBIT growth 1Y51.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.59%
EBIT Next 3Y26.9%
EBIT Next 5Y17.21%
FCF growth 1Y91.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.49%
OCF growth 3YN/A
OCF growth 5YN/A